The Lynx Group
Cholangiocarcinoma News

June/July 2022, Vol 3, No 2

There is a desperate need for patients with CCA to gain access to clinical trials to help improve survival.
Read More

A phase 3 study showed that the addition of cytotoxic chemotherapy to the PD-L1 inhibitor durvalumab was associated with promising antitumor activity as first-line treatment for patients with advanced BTC.
Read More

Dr Flavio Rocha, Chief of Surgical Oncology and Physician-in-Chief of the Knight Cancer Institute at Oregon Health & Science University, reviewed key abstracts on CCA and other biliary tract cancers presented at the IHPBA Congress.
Read More


In a Cholangiocarcinoma (CCA) Foundation meeting session, Dr Francesco Facchinetti from the Gustave Roussy Cancer Campus discussed novel approaches to overcome FGFR resistance in FGFR-altered CCA.
Read More

In a Cholangiocarcinoma (CCA) Foundation meeting session, Dr Zachariah H. Foda from the Johns Hopkins School of Medicine discussed the role of circulating tumor DNA (ctDNA) in early detection and disease monitoring for CCA.
Read More

At the CCA Foundation meeting, Dr Mark Yarchoan from the Johns Hopkins School of Medicine presented his fellowship project focused on deciphering immune micro-environments in molecularly defined CCA subsets.
Read More

At the 2022 annual meeting of the Cholangiocarcinoma Foundation, a case-based panel discussion focused on multidisciplinary care of cholangiocarcinoma.
Read More

Rachna T. Shroff, MD, MS, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, Tucson, reviewed promising clinical data regarding novel targeted therapies currently under clinical investigation for the treatment of cholangiocarcinoma (CCA)
Read More

At the 2022 Cholangiocarcinoma Foundation annual meeting, Dr Shahid Khan, Clinical Senior Lecturer at Imperial College London, discussed the need for correct International Classification of Diseases (ICD) coding for CCA.
Read More

Page 1 of 2


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: